Literature DB >> 1280578

Preventing long term complications. Implications for combination therapy with acarbose.

B R Zimmerman1.   

Abstract

Long term complications continue to be the major source of morbidity and mortality in patients with diabetes. Acarbose could potentially help to reduce diabetic complications if it improved glucose control, reduced lipid levels and hyperinsulinaemia. Acarbose has been shown to effectively reduce postprandial hyperglycaemia and haemoglobin A1c. This effect might be helpful in patients with insulin-dependent diabetes mellitus, as insulin injections do not provide complete control of rises in postprandial glucose levels, and in patients with non-insulin-dependent diabetes mellitus, because it simplifies the treatment programme. If improved control is shown to reduce complications, acarbose may be helpful. Although acarbose does not reduce hyperinsulinaemia, it reduces lipid levels and thus could reduce the risk of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280578     DOI: 10.2165/00003495-199200443-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  25 in total

1.  Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies.

Authors:  B Feldt-Rasmussen; E R Mathiesen; T Jensen; T Lauritzen; T Deckert
Journal:  Diabetologia       Date:  1991-03       Impact factor: 10.122

2.  Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.

Authors:  C Schnack; R J Prager; J Winkler; R M Klauser; B G Schneider; G Schernthaner
Journal:  Diabetes Care       Date:  1989-09       Impact factor: 19.112

Review 3.  Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models.

Authors:  G M Reaven
Journal:  Diabetes Care       Date:  1991-03       Impact factor: 19.112

Review 4.  Effects of acarbose on serum lipoproteins in healthy individuals during prolonged administration of a fiber-free formula diet.

Authors:  I E Walter-Sack; G Wolfram; N Zöllner
Journal:  Ann Nutr Metab       Date:  1989       Impact factor: 3.374

5.  Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group.

Authors: 
Journal:  Diabetes Care       Date:  1987 Jan-Feb       Impact factor: 19.112

Review 6.  Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  S P Clissold; C Edwards
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

7.  Insulin and cardiovascular disease. Paris Prospective Study.

Authors:  A M Fontbonne; E M Eschwège
Journal:  Diabetes Care       Date:  1991-06       Impact factor: 19.112

Review 8.  Influence of the degree of control of diabetes on the prevention, postponement and amelioration of late complications.

Authors:  B R Zimmerman
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

9.  Pancreatic islet transplantation after upper abdominal exenteration and liver replacement.

Authors:  A G Tzakis; C Ricordi; R Alejandro; Y Zeng; J J Fung; S Todo; A J Demetris; D H Mintz; T E Starzl
Journal:  Lancet       Date:  1990-08-18       Impact factor: 79.321

Review 10.  Metabolic effects of acarbose in young healthy men.

Authors:  C Couet; M Ulmer; M Hamdaoui; H M Bau; G Debry
Journal:  Eur J Clin Nutr       Date:  1989-03       Impact factor: 4.016

View more
  4 in total

Review 1.  Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.

Authors:  L J Scott; C M Spencer
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 2.  Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

Authors:  André J Scheen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.

Authors:  F Santeusanio; P Compagnucci
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

Review 4.  Glycaemia control in diabetes mellitus. Towards the normal profile?

Authors:  B R Zimmerman
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.